MAP2K1 and acute myeloid leukemia: In this study, we investigated both the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib in AML cells in order to identify a potentially effective treatment for subgroups of AML patients unfit for intensive chemotherapy.